A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in
combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in
patients with active rheumatoid arthritis (RA) who are incomplete responders to MTX.